CDDO-EA is widely studied for its potential therapeutic applications, particularly in the fields of oncology and inflammation. It has shown promising results in preclinical studies as an anti-cancer agent, where it induces apoptosis and inhibits the proliferation of various cancer cell lines. Additionally, CDDO-EA exhibits strong anti-inflammatory properties by modulating key signaling pathways such as NF-κB and Nrf2, making it a candidate for treating inflammatory diseases like arthritis and asthma. Its antioxidant effects further contribute to its protective role against oxidative stress-related conditions, including neurodegenerative disorders. Research is ongoing to explore its efficacy and safety in clinical settings.